Main

August 21, 2006

Distorted rectal tissue on prostate needle biopsy: a mimicker of prostate cancer.


Distorted rectal tissue on prostate needle biopsy: a mimicker of prostate cancer.
Related Articles

Distorted rectal tissue on prostate needle biopsy: a mimicker of prostate cancer.

Am J Surg Pathol. 2006 Jul;30(7):866-70

Authors: Schowinsky JT, Epstein JI

Rectal tissue is often seen in needle biopsies of the prostate gland. On rare occasion distorted rectal glands can mimic prostatic adenocarcinoma, an issue not previously addressed in the peer-reviewed literature. We evaluated 16 prostate needle biopsies received in consultation where the submitting pathologist questioned whether a focus of rectal tissue was prostate cancer. In addition to the distorted architecture, features mimicking prostate cancer included: (1) blue-tinged intraluminal mucinous secretions in 10 cases (63%), (2) prominent nucleoli in 6 cases (37%), (3) mitotic activity in 6 cases (37%), (4) extracellular mucin in 5 cases (31%), and (5) adenomatous changes of the rectal tissue in 1 case (6%). Immunohistochemical results further mimicked prostate cancer with negative stains for the basal cell markers high-molecular weight cytokeratin (n=6) and p63 (n=4), and positive stains for racemase in 4 of 5 biopsies. Diagnostic clues to recognizing that these foci were distorted rectal fragments were the presence of (1) lamina propria in 12 cases (75%), (2) rectal tissue located on a detached fragment of tissue in 10 biopsies (63%), (3) associated inflammation in 10 cases (63%), (4) goblet cells in 7 cases (44%), and (5) muscularis propria in 6 cases (37%). In 2 cases, there was negative staining for prostate specific antigen (PSA) and in 1 case negative staining for cytokeratin 7 and positivity for cytokeratin 20. Rectal glands are associated with many of the classical features of prostate cancer, and immunohistochemistry may be misleading. Recognition of these features mimicking prostate cancer and awareness of other findings that are diagnostic of rectal tissue on biopsy can prevent a misdiagnosis of atypical prostate glands or prostate cancer.

PMID: 16819329 [PubMed - indexed for MEDLINE]


August 09, 2006

prostate cancer surgery; +260 new citations


prostate cancer surgery; +260 new citations

260 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results:

prostate cancer surgery

These PubMed results were generated on 2006/08/09

PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources.


June 05, 2006

Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?


Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Related Articles

Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?

Urology. 2006 May;67(5):1084.e15-7

Authors: Daskivich TJ, Oh WK

We describe a patient with advanced prostate cancer who failed to achieve testosterone suppression with depot leuprolide after developing sterile abscesses at the injection sites. When the patient was switched to depot goserelin, he did not have any evidence of inflammation at the injection sites, but testosterone suppression again failed. This case suggests variable mechanisms for failure of gonadotropin-releasing hormone agonist therapy and highlights the necessity of prospective testosterone monitoring in patients who have developed sterile abscesses, even if switched to another gonadotropin-releasing hormone agonist.

PMID: 16698377 [PubMed - indexed for MEDLINE]


May 24, 2006

Robotic prostatectomy: is it the future?


Robotic prostatectomy: is it the future?
Related Articles

Robotic prostatectomy: is it the future?

Urol Oncol. 2006 Jan-Feb;24(1):1-3

Authors: Ahlering TE

PMID: 16414485 [PubMed - indexed for MEDLINE]


May 21, 2006

[Clinicopathological study of incidental cancer prostate in patients undergoing surgery for symptomatic diagnosis of BPH]


[Clinicopathological study of incidental cancer prostate in patients undergoing surgery for symptomatic diagnosis of BPH]
Related Articles

[Clinicopathological study of incidental cancer prostate in patients undergoing surgery for symptomatic diagnosis of BPH]

Actas Urol Esp. 2006 Jan;30(1):33-7

Authors: Fernández Rosado E, Gómez Veiga F, Alvarez Castelo L, Ruibal Moldes M, Chantada Abal V, González Martín M

OBJECTIVES-INTRODUCTION: Retrospective study of a series of patients with prostate surgery (suprapubic prostate adenomectomy -APS-, and prostate transurethral resection -RTU-P-) for presumed BPH symptomatic non-respondent to the conservative medical treatment. Analysis of prevalence, incidence, clinical-pathological, treatment, tumor progression and evolution of the patients with incidental prostate cancer (CPI) detected. MATERIAL AND METHODS: 1593 patients with prostate surgery (APS and RTU-P) during 6 years (1996-2001) were revised. APS 35%, RTU-P 65%. Revision of all pathological anatomy of surgical specimens and the evolutions of the patients with CPI. RESULTS: 78 CPI; Prevalence 4,89%; Incidence 13 cases/year. Mean age 73.6 years. Digital rectal examination was normal in 100%, mean PSA 6 ng/ml (0.5-30). Group APS: 25 CPI (32%); prevalence 4.55%; incidence 4 cases/year; mean PSA 7.7 ng/ml (2.8-30); mean weight resection 65 gs. Group RTU-P: 53 CPI (68%); prevalence 5,07%; incidence 9 cases/year; mean PSA 5.2 ng/ml (0,5-29); mean weight resection 20 gs. 22% biopsy previously by high PSA, mean PSA 14 ng/ml (4,8-30). Gleason average 5 (mean 4.8), rank 3-8. pTla 66%, pTlb 33%. Treatment: 57% follow-up watched without treatment (wait and see); 18% hormonal treatment; 3% finasteride; 9% Radical Prostatectomy; 9% radiotherapy. Follow Lost 4%. Mean follow-up 47.19 months (12-96). Tumor progression 13.3% (10 patients). Specific CPI mortality 2.6% (2 patients). CONCLUSIONS: We didn't observe significant differences between the prevalence of CPI in both groups (APS and RTU-P). The detected tumours were mainly well differentiated and in stage pTla. In more than half of the cases an expectant attitude without treatment was decided. 13,3% of tumor progression after 47.19 months of follow mean and specific CPI mortality 2.6%.

PMID: 16703727 [PubMed - in process]


May 15, 2006

Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis.


Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis.
Related Articles

Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis.

Urology. 2006 May 5;

Authors: Berglund RK, Jones JS, Ulchaker JC, Fergany A, Gill I, Kaouk J, Klein EA

OBJECTIVES: Locally advanced prostate cancer is frequently treated with radiotherapy and androgen deprivation because of the greater rate of extracapsular disease and the concern that radical prostatectomy (RP) may not be curative in most cases. A case for surgery for locally advanced disease may be made on the basis of a lower rate of local recurrence compared with radiotherapy in our comparative database, data suggesting a survival advantage with pelvic lymph node dissection in those with positive nodes, and the observation of improved survival in those with metastatic disease treated by RP compared with radiotherapy. We report on the feasibility of RP as a primary treatment modality for locally advanced disease. METHODS: A total of 281 consecutive patients treated by RP between January 1998 and June 2004 were reviewed. Locally advanced disease was defined as clinical Stage T2b or worse, prostate-specific antigen level greater than 15 ng/mL, and/or a Gleason score of 8 or greater. Data on the pathologic characteristics, operative complications, and follow-up were obtained from a prospectively maintained institutional review board-approved database. RESULTS: Pathologic examination demonstrated organ-confined disease in 11.7%, extracapsular extension in 56.9%, seminal vesicle involvement in 23.1%, and positive lymph nodes in 8.9%. The overall complication rate was 9.7% compared with 6.9% for all patients undergoing RP. At a mean follow-up of 34 months (range 1 to 78), 198 (70.4%) of 281 patients had an undetectable prostate-specific antigen level at the last follow-up examination. CONCLUSIONS: RP for locally advanced prostate cancer is feasible, with acute morbidity similar to RP for more localized disease. Furthermore, RP results in short-term biochemical recurrence-free survival similar to that of combined radiotherapy and androgen ablation.

PMID: 16678888 [PubMed - as supplied by publisher]


May 04, 2006

Being screened for prostate cancer: a simple blood test or a commitment to treatment?


Being screened for prostate cancer: a simple blood test or a commitment to treatment?
Related Articles

Being screened for prostate cancer: a simple blood test or a commitment to treatment?

Cancer Nurs. 2006 Jan-Feb;29(1):1-8

Authors: Oliffe J

The virtues of screening men for prostate cancer continue to be debated in political and public health, as well as clinical forums. Science has been unable to accurately predict screening benefits, yet many men are required to make informed decisions about prostate cancer screening. Clinicians' screening practices have been reported, but little research attention has been given to patients' experiences. The purpose of this study was to describe patients' perspectives of being screened and subsequently diagnosed with prostate cancer. Thirty-five Anglo-Australian men were interviewed, and the data were analyzed using ethnographic content analysis. The findings indicated that most participants experienced screening as a continuum of 3 tests, rather than the simple prostate-specific antigen blood test they had often anticipated. Commitment to a definitive diagnosis when abnormality was detected through screening and uptake of active treatment(s) when prostate cancer was confirmed were strongly represented in this study. The findings offer insight to the complex and often rapid sequence of events that can accompany prostate cancer screening. This has implications for the information that needs to be discussed with men before, rather than after prostate cancer screening has commenced.

PMID: 16557114 [PubMed - indexed for MEDLINE]


May 02, 2006

prostate cancer surgery; +55 new citations


prostate cancer surgery; +55 new citations

55 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results:

prostate cancer surgery

These PubMed results were generated on 2006/05/02

PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources.


April 18, 2006

Robot-assisted needle placement in open-MRI: system architecture, integration and validation.


Robot-assisted needle placement in open-MRI: system architecture, integration and validation.
Related Articles

Robot-assisted needle placement in open-MRI: system architecture, integration and validation.

Stud Health Technol Inform. 2006;119:126-31

Authors: DiMaio SP, Pieper S, Chinzei K, Hata N, Balogh E, Fichtinger G, Tempany CM, Kikinis R

This work describes an integrated system for planning and performing percutaneous procedures-such as prostate biopsy-with robotic assistance under MRI-guidance. The physician interacts with a planning interface in order to specify the set of desired needle trajectories, based on anatomical structures and lesions observed in the patient's MR images. All image-space coordinates are automatically computed, and used to position a needle guide by means of an MRI-compatible robotic manipulator, thus avoiding the limitations of the traditional fixed needle template. Direct control of real-time imaging aids visualization of the needle as it is manually inserted through the guide. Results from in-scanner phantom experiments are provided.

PMID: 16404030 [PubMed - indexed for MEDLINE]


April 12, 2006

prostate cancer surgery; +88 new citations


prostate cancer surgery; +88 new citations

88 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results:

prostate cancer surgery

These PubMed results were generated on 2006/04/13

PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources.


March 21, 2006

Maintaining bone health in patients with prostate cancer.


Maintaining bone health in patients with prostate cancer.
Related Articles Maintaining bone health in patients with prostate cancer. Med J Aust. 2006 Feb 20;184(4):176-9 Authors: Holmes-Walker DJ, Woo H, Gurney H, Do VT, Chipps DR Loss of bone mineral density with androgen deprivation therapy (ADT) for prostate cancer is well recognised, with significant loss of bone mineral density (BMD) occurring within 12 months of starting therapy. With ADT, annual loss of BMD is about 2%-8% per year at the lumbar spine and 1.8%-6.5% at the hip; the loss appears to continue indefinitely while treatment continues, and there is no recovery after therapy is ceased. 19.4% of men surviving at least 5 years after diagnosis of prostate cancer have a fracture if treated with ADT compared with 12.6% of men not receiving ADT; this is equivalent to one additional fracture for every 28 men treated with ADT. Vitamin D deficiency exacerbates the development of osteoporosis, so vitamin D status should be evaluated before commencing ADT in men with prostate cancer. Treatment with bisphosphonates (zoledronate, pamidronate and alendronate) in men treated with ADT have been shown to prevent bone loss in prospective studies and to increase BMD in one randomised controlled trial; bisphosphonates have not been shown to prevent fractures in men with prostate cancer. Further prospective trials are required to assess the efficacy and cost-effectiveness of bisphosphonates in men with prostate cancer who require treatment with ADT. All doctors need to take an active role in monitoring bone health in patients with prostate cancer requiring ADT. PMID: 16489902 [PubMed - indexed for MEDLINE]

March 16, 2006

Urinary incontinence and voiding dysfunction after radical retropubic prostatectomy (prospective urodynamic study).


Urinary incontinence and voiding dysfunction after radical retropubic prostatectomy (prospective urodynamic study).
Related Articles Urinary incontinence and voiding dysfunction after radical retropubic prostatectomy (prospective urodynamic study). Neurourol Urodyn. 2006;25(1):2-7 Authors: Majoros A, Bach D, Keszthelyi A, Hamvas A, Romics I AIMS: During this prospective study we analyzed the effects of radical retropubic prostatectomy (RRP) on bladder and sphincter function by comparing preoperative and postoperative urodynamic data. The aim of the study was to determine the reason for urinary incontinence after RRP and explain why one group of patients will be immediately continent after catheter removal, while others need some time to reach complete continence. METHODS: Urodynamic examination was performed in 63 patients 3-7 days before and 2 months after surgery. RESULTS: Forty-three (68.2%) and 53 (84.1%) patients regained continence at 2 and 9 months following RRP, respectively. Ten patients (15.9%) were immediately continent after catheter removal. Urodynamic stress incontinence was detected in 18 (28.6%), and detrusor overactivity incontinence in 2 (3.2%) patients 2 months after surgery. The amplitude of preoperative maximal voluntary sphincteric contractions was significantly higher in the postoperative continent group (125 vs. 96.5 cmH(2)O, P < 0.0001). The patients who were immediately continent following catheter removal had no lower urinary tract symptoms (LUTS) and urodynamic abnormality preoperatively, and they had significantly higher preoperative and postoperative maximum urethral closure pressure (at rest and during voluntary sphincter contraction) than those who became continent later on. CONCLUSIONS: These data suggest that the main cause of incontinence after RRP is sphincteric weakness. In the continent group, those who became immediately continent had significantly higher maximum urethral closure pressure values at rest and at voluntary sphincteric contraction even before the surgery. PMID: 16224797 [PubMed - indexed for MEDLINE]

March 15, 2006

[Volume and health outcomes: an overview of systematic reviews]


[Volume and health outcomes: an overview of systematic reviews]
Related Articles [Volume and health outcomes: an overview of systematic reviews] Epidemiol Prev. 2005 May-Aug;29(3-4 Suppl):3-63 Authors: Davoli M, Amato L, Minozzi S, Bargagli AM, Vecchi S, Perucci CA BACKGROUND: Improving quality and effectiveness of health care is one of the priorities of health policies. Hospital or physician volume of activity may be a measurable variable with a relevant impact on effectiveness of health care. There are several studies and systematic reviews evaluating the association between volume and outcome of health care. The aim of this review is to identify: areas, clinical conditions or interventions (prevention, diagnostic, therapeutic, surgical or clinical) for which an association between volume and outcome has been investigated; those for which an association between volume and outcome has been proved METHODS: Overview of systematic reviews and Health Technology Assessment reports; search of MEDLINE, EMBASE, The Cochrane Library, Web sites of Health Technology Assessment, other HTA Agencies, National guideline Clearinghouse, National Health Care quality tools (1995-february 2005). For each studied area results are described separately for each review due to the heterogeneity of outcomes, volume thresholds and results reported. No metanalysis has been conducted. Completeness of reporting of the systematic reviews has been evaluated using the QUOROM statement. For each review we evaluated the number of studies included and the proportion of studies with statistically significant results (p < 0,05). As far as in-hospital mortality is concerned, the different areas have been classified in the following groups: Strong evidence ofpositive association: areas with > or =10 studies included in the reviews, and high prevalence (> or =50%) of positive studies (p <0. 05) in the majority of reviews. Weak evidence of association: areas with 5 to 9 studies included in the reviews and high prevalence (> or =50%) of positive studies (p <0.05) in the majority of reviews. Weak evidence of lack of association: areas with 5 to 9 studies included in the reviews and high prevalence (>50%) of not statistically significant studies (p >0.05) in the majority of reviews. No suficient evidence of association: areas with less than 5 studies included in the reviews. No evidence of association: areas with > or =10 studies included in the reviews, and high prevalence (>50%) of not statistically significant studies (p >0.05) in the majority of reviews. The same literature search was then applied to identify primary studies published in each considered area following the most recent systematic review published. RESULTS AND DISCUSSION: We identified 21 systematic reviews and included 11 of them analysing 46 different areas. The majority of studies evaluate the effect of specific surgical procedures; the main outcomes considered are hospital mortality and 5 year survival for cancers. Considering in-hospital mortalilty as outcome, in 11 areas there is strong evidence ofassociation between volume of activity and outcome: abdominalaortic aneurysm (unruptured), percutaneous transluminal coronary angioplasty knee arthroplasty coronary artery bypass, surgery for oesophageal and pancreatic cancer, surgery for prostate cancer, colecistectomy, carotid endarterectomy, myocardial infarction, neonatal intensive care. It is never possible however to identify a unique volume threshold. For some of these areas, particularly coronary angioplasty and coronary artery bypass, there are many new studies published following the last systematic review; some specific aspects are being investigated such as the role of temporal changes in the association, the effect of different risk adjustment procedures and the separate role of physician or hospital volume. In some cases, for example knee arthroplasty in-hospital mortality could be an inadequate outcome on which judging the strength of association, in fact, the few studies evaluating other outcomes such as complications provide inconsistent results. For a range of areas the evidence of association is weak: AIDS, appendicectomy, cardiac catheterization, surgery for breast, lung, stomach cancer, hernia repair, hip fracture, hysterectomy and injuries. As far as AIDS is concerned, the few number of studies found is probably due to the lack of studies published after the introduction of effective therapies. All the included studies show an evidence of association between volume and in-hospital mortality. In no case we found weak evidence of lack of association while we identified three conditions for which the number of studies included in the reviews together with the prevalence of non significant studies do suggest lack of association; these are abdominal aortic aneurysm (ruptured), hip arthroplasty and surgery for colorectal cancer. In the case of hip arthroplasty as well, inhospital mortality could be an inadequate outcome, but only one old study found a positive association with risk of complications. Eventually there is a group of areas (n=22) for which there is not enough evidence to draw conclusions about the association between volume and outcome due to a small number of studies. In some cases, such as transplants, this could be due to the low rate of events; in this case all the few published studies show positive results. There are some limitations which should be taken into account in the interpretation of these results: despite the overall good completeness of reporting of the included reviews, the majority of studies included in the reviews themselves are cross-sectional studies representing a very weak study design to evaluate causality of the investigated association. Moreover the methodology of risk adjustment applied is heterogenous among studies and it is difficult to know the extent to which this can affect the observed results. It is eventually necessary to consider the possible occurrence of publication bias which could lead to an overestimation of the positive effect of volume on health care outcomes attributable to the lack of publication of negative studies. CONCLUSIONS: In some areas the evidence seems strong enough to guide health care organizational choices, although it is not possible to identify well defined volume thresholds. In other areas, particularly for non surgical conditions, where there is not enough evidence, it seems necessary to conduct proper epidemiological studies. Also the evaluation of effectiveness of using volume as an instrument of health policy requires further research. Taking into account the rapid and continuing process of technology development, the definition of standard and prerequisite volumes of care should be specific of each temporal period and health care system. It is therefore a dynamic process requiring a continuous review of the available evidence. In the area of evidence based public health, the limited available evidence should not impair the choice of actions based on limited evidence, but rather it should lead to the application of thefew available evidence on one side and to the planning of proper research in the areas of lack of evidence. PMID: 16529350 [PubMed - in process]

March 12, 2006

prostate cancer surgery; +83 new citations


prostate cancer surgery; +83 new citations
83 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: prostate cancer surgery These PubMed results were generated on 2006/03/12PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources.

February 27, 2006

[Results of a series of transrectal ultrasound guided biopsy of the prostate in 6000 patients. Part II: PSA derived parameters]


[Results of a series of transrectal ultrasound guided biopsy of the prostate in 6000 patients. Part II: PSA derived parameters]
Related Articles [Results of a series of transrectal ultrasound guided biopsy of the prostate in 6000 patients. Part II: PSA derived parameters] Arch Esp Urol. 2005 Sep;58(7):623-34 Authors: Rodr guez-Patr n Rodr guez R, Mayayo Dehesa T, Burgos Revilla FJ, Alonso Gonz lez M, Lennie Zucharino A, Garc a Gonz lez R OBJECTIVES: We review the results of 6000 patients with the clinical suspect of prostate cancer who underwent one or more prostate, biopsies, analyzing the role of PSA derived parameters in the probability of having prostate cancer in the TRUS biopsy. METHODS: We selected 6000 patients who under- went TRUS biopsy between 1994 and 2002. 861 of them underwent more than one is biopsy, adding up to a total of 7127 biopsies. For the study of PSA derived indexes we established ranges based on the 10th percentile for the first biopsy for all patients and also for those with PSA between 4 and 10 ng/ml. Several predictive models were determined by logistic regression of the variables related with presence/no presence of cancer. RESULTS: For first biopsies the ranges of PSAD established showed a diagnostic effectiveness below 8% with PSA densities lower than 0.11 ng/ml/cc. The free/total PSA ratio is less discriminant in the ranges obtained with a 13.7% incidence of prostate cancer for values above 0.24. In the case of second biopsies the group of patients with PSAD below 0.12 had only a 5.3% incidence, and only one patient with F/T PSA ratio higher than 0.24 had a prostate cancer (2.9%). All studied parameters but F/T PSA ratio showed statistical significance in the multivariant analysis. CONCLUSIONS: Although the establishment of a cut point for PSAD diminishes sensitivity, prostate biopsy habits should be modified assuming the loss of tumors in patients with low PSAD and increasing the number of biopsies in patients with total PSA values below 4 ng/ml with higher densities. PMID: 16294784 [PubMed - indexed for MEDLINE]

February 20, 2006

[Advancement of treatment for prostate cancer.]


[Advancement of treatment for prostate cancer.]
Related Articles [Advancement of treatment for prostate cancer.] Gan To Kagaku Ryoho. 2006 Feb;33(2):178-82 Authors: Hara I The number of prostate cancer patients is rapidly increasing in Japan,as aging people are more common and the lifestyle is more westernized. Another reason is that prostate specific antigen(PSA) is prevalent and PSA test can detect organ-confined prostate cancer in the early stage. In the past, endocrine therapy was the main treatment modality since many prostate cancer patients were diagnosed in the advanced stage. However, endocrine therapy is not suitable for young patients with organ-confined prostate cancer. Surgery and radiation therapy are becoming standard therapy for these patients. Although retropubic radical prostatectomy is widely performed,urinary incontinence and sexual dysfunction are still problems. Other approaches such as laparoscopic rostatectomy, portless endoscopic prostatectomy and perineal prostatectomy are also performed. Radiation therapy is commonly used for organ-confined prostate cancer in Europe and the U.S.A. The advancement in computer technology has made it possible to accumulate enough radiation dose to target without damaging the surrounding organs(3 D conformal, intensity-modulated radiotherapy). Heavy ion particle radiotherapy is also attempted in some institutes.Moreover, brachytherapy can be another choice in radiation therapy. In Japan, only high-dose brachytherapy with (192)Ir has been performed. In July 2003,permanent seed brachytherapy with (121)I was legally approved in Japan, and more organ-confined prostate cancer patients are expected to undergo this treatment. There are several treatment modalities for organ-confined prostate cancer patients these days. Therefore, not only tumor grade and stage, but also patients'lifestyle and thought should be considered in determining treatment. PMID: 16484852 [PubMed - in process]

February 15, 2006

Robotic extraperitoneal radical prostatectomy: an alternative approach.


Robotic extraperitoneal radical prostatectomy: an alternative approach.
Related Articles Robotic extraperitoneal radical prostatectomy: an alternative approach. J Urol. 2006 Mar;175(3):945-51 Authors: Joseph JV, Rosenbaum R, Madeb R, Erturk E, Patel HR PURPOSE: Laparoscopic radical prostatectomy with or without a robot has been increasingly performed worldwide, primarily using a transperitoneal approach. We report our experience with daVinci(R) robot assisted extraperitoneal laparoscopic radical prostatectomy. MATERIALS AND METHODS: A total of 325 patients underwent robot assisted extraperitoneal laparoscopic radical prostatectomy for clinically localized prostate cancer at our center during a 2-year period. Perioperative data, and oncological and functional results were prospectively recorded. RESULTS: Perioperative demographics included mean age, PSA and Gleason score, which were 60 years (range 42 to 76), 6.6 ng/ml (range 0.6 to 26) and 6 (range 5 to 9), respectively. Preoperative clinical stage was 81%, 16% and 3% for T1c, T2a and T2b, respectively. Average total operative time was 130 minutes (range 80 to 480). Intraoperative data included a mean blood loss of 196 cc with no open conversions. Bilateral, unilateral and nonnerve sparing prostatectomy was performed in 70%, 24% and 6% of patients, respectively. Of the patients 96% were discharged home within 8 to 23 hours of surgery. Pathological stage was pT2a, pT2b, pT3a and pT3b in 18%, 63%, 14% and 5% of all radical prostatectomy specimens, respectively, with an overall positive surgical margin rate of 13%. Two of 92 patients had positive nodal disease after lymph node dissection. Continence and erectile function were measured. CONCLUSIONS: The extraperitoneal approach offers the advantages of improved dexterity and visualization of the robot, while avoiding the abdominal cavity and potential associated morbidity. As surgeons gain more experience with this new technology, the extraperitoneal approach simulating the standard open retropubic technique is likely to gain popularity. PMID: 16469589 [PubMed - in process]

February 14, 2006

Salvage surgery in prostate cancer: assessment of rectal wall invasion.


Salvage surgery in prostate cancer: assessment of rectal wall invasion.
Related Articles Salvage surgery in prostate cancer: assessment of rectal wall invasion. Nat Clin Pract Urol. 2005 Jan 16;2(1):5 Authors: PMID: 16474556 [PubMed - as supplied by publisher]

Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study.


Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study.
Related Articles Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. Clin Cancer Res. 2005 Nov 15;11(22):8109-13 Authors: Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW, PURPOSE: Analyzing metastatic prostate cancer tissue is of considerable importance in evaluating new targeted agents, yet acquiring such tissue presents a challenge due to the predominance of bone metastases. We assessed factors predicting a successful tumor harvest from bone marrow biopsies (BMBx) in castration-resistant metastatic prostate cancer patients. MATERIAL AND METHODS: Data from Cancer and Leukemia Group B study 9663 were reviewed. Bone marrow biopsies were obtained from 184 patients who underwent an office-based, unguided bone marrow biopsy of the posterior iliac crest. RESULTS: Forty-seven of the 184 patients (25.5%) had a positive bone marrow biopsy. When considered in a multivariate logistic regression analysis, lower hemoglobin levels, higher alkaline phosphatase, and higher lactate dehydrogenase levels were associated with a higher likelihood of a positive BMBx. The median survival time was 11 months (95% confidence interval, 8.0-14) among patients with a positive BMBx compared with 23 months (95% confidence interval, 19-27) with a negative BMBx. The median time to progression and time to prostate-specific antigen progression-free survival were also significantly decreased among positive BMBx patients. No patients with a positive BMBx survived beyond 3 years, whereas 11 of the 137 patients with a negative BMBx survived beyond 5 years. DISCUSSION: Using common laboratory values, a specific patient cohort can be defined from whom the yield of a nonguided BMBx would be high enough to justify this approach. For studies that require broader entry criteria, a more directed approach with image guidance is recommended. PMID: 16299243 [PubMed - indexed for MEDLINE]

February 13, 2006

Value of prostate volume measurement using transabdominal ultrasonography for the improvement of prostate-speci fi c antigen-based cancer detection.


Value of prostate volume measurement using transabdominal ultrasonography for the improvement of prostate-speci fi c antigen-based cancer detection.
Related Articles Value of prostate volume measurement using transabdominal ultrasonography for the improvement of prostate-speci fi c antigen-based cancer detection. Int J Urol. 2005 Oct;12(10):881-5 Authors: Kobayashi T, Kawahara T, Nishizawa K, Ogura K, Mitsumori K, Ide Y PURPOSE: To examine value of prostate-speci fi c antigen (PSA) adjusted by prostate volume measured using transabdominal ultrasonography in prostate cancer detection among men with elevated PSA. METHODS: 238 men aged 79 years or younger with serum PSA levels of 2.0-20.0 ng/mL and normal digital rectal examination fi ndings were studied in terms of total and free PSA, prostate volumes with transrectal (TRUS) and transabdominal (TAUS) ultrasonography and transition zone volumes with TRUS prior to transrectal 10-core biopsy. In addition to sole PSA values and the free-to-total PSA ratio, volume-adjusted PSA values, PSA densities determined by TRUS (PSAD(TRUS)), and TAUS (PSAD(TAUS)), and PSA transition zone densities (PSATzD) were compared using receiver operating characteristic (ROC) analysis. RESULTS: Prostate cancer was diagnosed in 58 (24.4%) of the 238 men who underwent prostate biopsies. Of the areas under ROC curves (AUC) of studied parameters, PSATzD (AUC 0.751) was the best and signi fi cantly superior to PSAD(TAUS) (AUC 0.664, P = 0.007). However, PSAD(TAUS) exceeded PSA (AUC 0.559, P = 0.004) and showed potential capability of a one-fourth reduction in unnecessary biopsies without spoiling sensitivity (90%). Cancer detection rate was only 4.2% in the 48 patients whose prostate volume in TAUS was > 50 mL and PSAD(TAUS) was < 0.075. CONCLUSIONS: Since PSAD(TRUS) and PSATzD were signi fi cantly superior to PSAD(TAUS), TRUS is feasible as the standard fashion to determine prostate volume in the diagnosis of prostate cancers. However, TAUS is also worthwhile as it can improve the prostate cancer detection using sole PSA, and primary use of TAUS has the potential to reduce the substantial number of unnecessary biopsy safely. PMID: 16323981 [PubMed - indexed for MEDLINE]

Value of prostate volume measurement using transabdominal ultrasonography for the improvement of prostate-speci fi c antigen-based cancer detection.


Value of prostate volume measurement using transabdominal ultrasonography for the improvement of prostate-speci fi c antigen-based cancer detection.
Related Articles Value of prostate volume measurement using transabdominal ultrasonography for the improvement of prostate-speci fi c antigen-based cancer detection. Int J Urol. 2005 Oct;12(10):881-5 Authors: Kobayashi T, Kawahara T, Nishizawa K, Ogura K, Mitsumori K, Ide Y PURPOSE: To examine value of prostate-speci fi c antigen (PSA) adjusted by prostate volume measured using transabdominal ultrasonography in prostate cancer detection among men with elevated PSA. METHODS: 238 men aged 79 years or younger with serum PSA levels of 2.0-20.0 ng/mL and normal digital rectal examination fi ndings were studied in terms of total and free PSA, prostate volumes with transrectal (TRUS) and transabdominal (TAUS) ultrasonography and transition zone volumes with TRUS prior to transrectal 10-core biopsy. In addition to sole PSA values and the free-to-total PSA ratio, volume-adjusted PSA values, PSA densities determined by TRUS (PSAD(TRUS)), and TAUS (PSAD(TAUS)), and PSA transition zone densities (PSATzD) were compared using receiver operating characteristic (ROC) analysis. RESULTS: Prostate cancer was diagnosed in 58 (24.4%) of the 238 men who underwent prostate biopsies. Of the areas under ROC curves (AUC) of studied parameters, PSATzD (AUC 0.751) was the best and signi fi cantly superior to PSAD(TAUS) (AUC 0.664, P = 0.007). However, PSAD(TAUS) exceeded PSA (AUC 0.559, P = 0.004) and showed potential capability of a one-fourth reduction in unnecessary biopsies without spoiling sensitivity (90%). Cancer detection rate was only 4.2% in the 48 patients whose prostate volume in TAUS was > 50 mL and PSAD(TAUS) was < 0.075. CONCLUSIONS: Since PSAD(TRUS) and PSATzD were signi fi cantly superior to PSAD(TAUS), TRUS is feasible as the standard fashion to determine prostate volume in the diagnosis of prostate cancers. However, TAUS is also worthwhile as it can improve the prostate cancer detection using sole PSA, and primary use of TAUS has the potential to reduce the substantial number of unnecessary biopsy safely. PMID: 16323981 [PubMed - indexed for MEDLINE]

February 12, 2006

E-cadherin gene 3'-UTR C/T polymorphism is associated with prostate cancer.


E-cadherin gene 3'-UTR C/T polymorphism is associated with prostate cancer.
Related Articles E-cadherin gene 3'-UTR C/T polymorphism is associated with prostate cancer. Urol Int. 2005;75(4):350-3 Authors: Wu HC, Lai MT, Wu CI, Chen HY, Wan L, Tsai FJ, Chen WC INTRODUCTION: E-cadherin (CDH-1) is a cell-cell adhesive molecule which maintains cell integrity and communication between the intracellular and extracellular world. CDH-1 may therefore be related to carcinogenesis. A polymorphism located at the 3'-UTR of the CDH-1 gene is associated with stone disease; however, its relationship to prostate cancer has not been reported. We aimed to study whether there is an association between the 3'-UTR polymorphism and prostate cancer. MATERIALS AND METHODS: We collected 96 patients with prostate cancer and 114 normal controls for this study. The polymorphism of the CDH-1 gene was studied by polymerase chain reaction-based restriction analysis. RESULTS: There was a significant difference in genotype distribution of the CDH-1 gene polymorphism between cancer patients and normal controls (p < 0.001). The distribution of the CDH-1 gene CC genotype in prostate cancer patients (51.0%) was higher than in the controls (10.5%). The odds ratio for the CDH-1 'C' allele was 2.896 (95% CI = 1.908-4.396). There was no significant difference according to age, pathological grading, clinical staging, and responsiveness to hormonal therapy among patients. Only 3 patients (3.1%) had a history of urolithiasis. CONCLUSIONS: The CDH-1 gene 3'-UTR C/T polymorphism is associated with prostate cancer. The 'CC' homozygote indicates a relatively higher risk for developing prostate cancer than other genotypes. PMID: 16327305 [PubMed - indexed for MEDLINE]

February 09, 2006

Molecular alterations in primary prostate cancer after androgen ablation therapy.


Molecular alterations in primary prostate cancer after androgen ablation therapy.
Related Articles Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6823-34 Authors: Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, González S, Velasco A, Linehan WM, Matusik RJ, Price DK, Figg WD, Emmert-Buck MR, Chuaqui RF PURPOSE: After an initial response to androgen ablation, most prostate tumors recur, ultimately progressing to highly aggressive androgen-independent cancer. The molecular mechanisms underlying progression are not well known in part due to the rarity of androgen-independent samples from primary and metastatic sites. EXPERIMENTAL DESIGN: We compared the gene expression profiles of 10 androgen-independent primary prostate tumor biopsies with 10 primary, untreated androgen-dependent tumors. Samples were laser capture microdissected, the RNA was amplified, and gene expression was assessed using Affymetrix Human Genome U133A GeneChip. Differential expression was examined with principal component analysis, hierarchical clustering, and Student's t testing. Analysis of gene ontology was done with Expression Analysis Systematic Explorer and gene expression data were integrated with genomic alterations with Differential Gene Locus Mapping. RESULTS: Unsupervised principal component analysis showed that the androgen-dependent and androgen-independent tumors segregated from one another. After filtering the data, 239 differentially expressed genes were identified. Two main gene ontologies were found discordant between androgen-independent and androgen-dependent tumors: macromolecule biosynthesis was down-regulated and cell adhesion was up-regulated in androgen-independent tumors. Other differentially expressed genes were related to interleukin-6 signaling as well as angiogenesis, cell adhesion, apoptosis, oxidative stress, and hormone response. The Differential Gene Locus Mapping analysis identified nine regions of potential chromosomal deletion in the androgen-independent tumors, including 1p36, 3p21, 6p21, 8p21, 11p15, 11q12, 12q23, 16q12, and 16q21. CONCLUSIONS: Taken together, these data identify several unique characteristics of androgen-independent prostate cancer that may hold potential for the development of targeted therapeutic intervention. PMID: 16203770 [PubMed - indexed for MEDLINE]

February 08, 2006

Ablation of stage T1/T2 prostate cancer with permanent interstitial temperature self-regulating rods.


Ablation of stage T1/T2 prostate cancer with permanent interstitial temperature self-regulating rods.
Related Articles Ablation of stage T1/T2 prostate cancer with permanent interstitial temperature self-regulating rods. J Endourol. 2005 Sep;19(7):865-7 Authors: Tucker RD, Huidobro C, Larson T PURPOSE: To determine if stage T(1)/T(2) prostate cancer can be treated safely and effectively with interstitial thermal ablation. PATIENTS AND METHODS: Twenty patients with biopsy-confirmed prostate cancer were enrolled in the protocol. The average age was 71.0 years, and the pretreatment prostate specific antigen (PSA) concentration ranged from 2.5 to 10.7 ng/mL and the Gleason sum from 3 to 7. An array of small biocompatible magnetic alloy rods was placed in the patients percutaneously in a procedure analogous to the placement of brachytherapy seeds. Rods were placed end-to-end and no further than 1 cm apart; rods extended to the capsule and were placed at the capsule in the rectal grove. The rods are temperature self-regulating and heat to 70 degrees C when placed in an alternating magnetic field. Each patient was treated in a coil system that supplies a uniform magnetic field throughout the patient's pelvis for a single 60-minute session. Urethral cooling and rectal temperature monitoring was performed. Serial PSA was followed, and biopsy was performed 1 year post-treatment. RESULTS: Immediately after treatment, most PSA values increased dramatically but then fell to <1.0 ng/mL within 8 weeks. After 1 year, five patients had positive biopsies; these patients had significantly lower rodimplant densities. Eight patients reported erectile dysfunction, but none reported incontinence. Other complications were minor. CONCLUSION: The data suggest that this technique is well tolerated and safe and may be useful in certain patients with T(1)/T(2) prostate cancer. PMID: 16190846 [PubMed - indexed for MEDLINE]

February 07, 2006

Transrectal ultrasound guided biopsy for detecting early prostate cancer: An Indian experience.


Transrectal ultrasound guided biopsy for detecting early prostate cancer: An Indian experience.
Related Articles Transrectal ultrasound guided biopsy for detecting early prostate cancer: An Indian experience. Indian J Cancer. 2005 Jul-Sep;42(3):151-4 Authors: Gupta NP, Ansari MS, Dass SC BACKGROUND: With the advent of prostate specific antigen the number of patients undergoing prostate biopsy has dramatically increased. The sextant biopsy technique has been conventionally used for the diagnosis of prostate cancer. Recently, concern has arisen that the original sextant method may not include an adequate sample of the prostate, hence it may result in high false negative rates. We conducted a prospective study to determine whether the 5-region prostate biopsy technique significantly increases the chance of prostate cancer detection as compared to the sextant biopsy technique. AIMS: To evaluate the efficacy of TRUS guided sextant and 5-region biopsy techniques in detecting carcinoma prostate in patients with PSA between 4 and 10 ng/ml and normal digital rectal examination. METHODS AND MATERIAL: Between December 2001 and August 2003 one forty-two men, aged 49-82 years, who presented with LUTS, normal digital rectal examination (DRE) and PSA between 4 and 10 ng/ml underwent TRUS guided sextant prostate biopsy. Serum PSA was reassessed after 3 months in patients whose biopsies were negative for cancer. If PSA was still raised, the patients underwent extensive 5-region biopsy. RESULTS: Mean patient age was 64 years and median PSA was 6.9 ng/ml. TRUS guided sextant biopsy revealed adenocarcinoma prostate in 34 men (24%). Median Gleason score was 7. Seven men (4.9%) had cellular atypia and 3(2.1%) had prostatic intraepithelial neoplasia (high grade). On repeat PSA estimation after 3 months, 48 patients showed stagnant or rising trend for which they underwent TRUS guided 13-core biopsy. Five (10.4%) patients were detected to have adenocarcinoma on repeat biopsy. Biopsy negative patients are on regular follow up with yearly PSA estimation. Complications included transient mild haematuria in14 patients (9.82%) and haematospermia in 4 (2.8%). Urinary retention developed in one patient and required an indwelling catheter for 4 days. CONCLUSION: Transrectal ultrasound guided sextant biopsy has shown a false negative rate of approximately 11%. A repeat 5- region (13-core) biopsy strategy can decrease the false negative rate of conventional sextant biopsy in patients with previously negative biopsies but persistently high PSA levels, high grade PIN or cellular atypia. PMID: 16276016 [PubMed - indexed for MEDLINE]

February 05, 2006

Complications following combined transrectal ultrasound-guided prostate needle biopsies and transurethral resection of the prostate.


Complications following combined transrectal ultrasound-guided prostate needle biopsies and transurethral resection of the prostate.
Related Articles Complications following combined transrectal ultrasound-guided prostate needle biopsies and transurethral resection of the prostate. Arch Androl. 2006 Mar-Apr;52(2):123-7 Authors: Shen BY, Chang PL, Lee SH, Chen CL, Tsui KH In order to evaluate safety and morbidity aspects of additional systematic prostate biopsies, we have conducted a retrospective review of patients who had undergone transurethral resection of the prostate (TUR-P) combined with additional systemic prostate needle biopsies at the Chang Gung Memorial Hospital. To this end, the records of 80 men presenting consecutively at our institution between February 2001 and January 2004 inclusively were examined. These 80 individuals included patients experiencing obstructive voiding symptoms and those featuring suspicious screening parameters, all of whom were to undergo transurethral resection of the prostate for symptomatic benign prostatic hyperplasia (BPH), all procedures being performed by a single surgeon. A total of 20 (25%) specimens were found to be positive for prostate cancer. Cancer was detected in the transrectal prostate biopsy specimen of 16 of 57 men (28%) who had not undergone a previous prostate biopsy, and for four of 23 (17%) who had undergone at least one previous (benign) biopsy. Mild complications associated with transurethral prostrate resection, such as hematuria and hemospermia, were reported frequently, featuring rates of 10% and 2.5%, respectively; more severe complications being noted far less frequently. Fever, usually of a low grade, was observed post-operatively for six (7.5%) patients, but a prompt return to normal temperature following antibiotic treatment for one day was revealed. Four (5%) patients remained admitted to the hospital for a prolonged period following surgery. A review of the literature concerning transrectal biopsies and TUR-P has shown that surgery-associated complication rates are slightly lower than was the case for our study. Additional systematic prostate biopsies for patients undergoing TUR-P would appear to be a relatively safe treatment procedure. Identification of risk factors for post-surgery complications might further improve the safety of the screening procedure. PMID: 16443589 [PubMed - in process]

January 30, 2006

Recent trends in surgical treatment of localized prostate cancer.


Recent trends in surgical treatment of localized prostate cancer.
Related Articles Recent trends in surgical treatment of localized prostate cancer. Clin Prostate Cancer. 2005 Sep;4(2):130-3 Authors: Link BA, Culkin DJ Prostate cancer and its various forms of treatment remain a source of significant controversy and morbidity despite recent advances. In response, there is an increasing trend toward the development of treatments aimed at cancer prevention and at maximizing the preservation of function without sacrificing cancer control. This article reviews the current prostate cancer literature and reports on improvements in existing surgical treatments and developing technologies aimed toward achieving these goals. Specific therapies addressed include improvements in surgical techniques, laparoscopy, robotics, cryosurgical and thermal ablation, and high-intensity focused ultrasound. PMID: 16197615 [PubMed - indexed for MEDLINE]

January 29, 2006

High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: technical description and preliminary experience.


High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: technical description and preliminary experience.
Related Articles High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: technical description and preliminary experience. Clin Transl Oncol. 2005 Oct;7(9):389-97 Authors: Prada G mez PJ, de la Rua Calder n A, Romo Fonseca I, Evia Su rez M, Abascal Garc a JM, Juan Rijo G, Fern ndez Garc a J, Gonz lez Sancho JM, Abascal Garc a R, Rodr guez-Fern ndez R INTRODUCTION. It has been well documented that the outcome of prostate cancer treatment depends on the dose administered. Hence, techniques have been developed that allow high-dose administration without increasing the complications, e.g. external radiotherapy combined with high-dose radiation (HDR) brachytherapy. In this article we analyse the technique and protocol of real-time HDR brachytherapy together with the preliminary results that support its use. Materials and methods. Between June 1998 and December 2004, 100 patients with adenoma of the prostate were treated with 46 Gy of external irradiation to the pelvis and 2 HDR brachytherapy fractions (each of 1150 cGy) at the end of weeks 1 and 3 of a 5-week radiotherapy course. The 1997 American Joint Commission on Cancer (AJCC) system was used to establish disease stage. Patients with intermediate-risk (PSA 10-20 ng/ml or Gleason = 7 or T2c) and high-risk (two intermediate risk factors or PSA > 20 ng/ml or Gleason > 7 or > T2c) without metastases were eligible for the brachytherapy. Biochemical failure was defined according to the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus panel statement. SPSS statistical package was used to quantify survival (Kaplan-Meier method). Toxicity was scored according to RTOG guidelines. RESULTS. The mean age of patients was 67 years (range 49-78). Clinical stage was T2a in 22% of the patients, 26% T2b and 52% T3. Initial PSA was = 10 ng/ml in 22% of the patients and > 10 ng/ml in 78%. Median follow-up was 28 months (range: 12-79). The 5-year overall survival and actuarial biochemical control were 99% and 87% respectively. No chronic severe complications were noted. CONCLUSIONS. The good results of local control, disease-free survival and few complications that the external radiotherapy combined with HDR brachytherapy have shown suggest that the method should be considered as first-choice in the treatment of prostate tumours of high- and intermediate-risk. PMID: 16238973 [PubMed - indexed for MEDLINE]

January 28, 2006

Managed care market share and primary treatment for cancer.


Managed care market share and primary treatment for cancer.
Related Articles Managed care market share and primary treatment for cancer. Health Serv Res. 2006 Feb;41(1):9-22 Authors: Keating NL, Landrum MB, Meara E, Ganz PA, Guadagnoli E Objective. Increases in the market share of managed care are associated with decreases in expenditures in the fee-for-service sector. To understand utilization patterns responsible for such savings, we assessed whether increases in managed care market share were related to increases in receipt of equally effective but less costly primary cancer therapies. Data Sources. Cancer registry data linked to Medicare administrative data for a population-based sample of fee-for-service Medicare beneficiaries 66 years and older who were diagnosed with breast or prostate cancer during 1993-1999. Study Design. We used fixed-effects regression models to assess whether county-level increases in the market share of managed care were associated with differences in receipt of cancer therapies that are similar in effectiveness but vary in cost. Principal Findings. Increases in the market share of managed care were not associated with differences in the receipt of mastectomy versus breast-conserving surgery with radiation for women with early stage breast cancer (p=.47) or with the receipt of conservative therapy (versus surgery or radiation therapy) for men with local or regional prostate cancer (p=.30). Conclusions. Increases in the market share of managed care do not appear to influence the receipt of equally effective primary treatments for cancer in the fee-for-service sector. PMID: 16430598 [PubMed - in process]

January 24, 2006

Evaluation of lipophilins as determinants of tumor cell response to estramustine.


Evaluation of lipophilins as determinants of tumor cell response to estramustine.
Related Articles Evaluation of lipophilins as determinants of tumor cell response to estramustine. J Pharmacol Exp Ther. 2005 Dec;315(3):1158-62 Authors: Tucker JM, Lipatova Z, Beljanski V, Townsend DM, Tew KD Estramustine administered orally as estramustine phosphate (EMP) remains a major tool in hormone refractory prostate cancer chemotherapy. The presence of estramustine binding protein, prostatin, in prostate tissue may be a determinant of response to treatment. Lipophilins are secretory proteins with homology to prostatin. Reverse transcription-polymerase chain reaction was performed to estimate expression patterns of lipophilins A to C in human biopsies and cell lines resistant to estramustine. Although lipophilin A was not expressed in prostate tissue, both lipophilins B and C were expressed in normal and tumor prostate without significant differences. For lipophilin C, a somatic mutation (T to C transition at positions 409 and 412) was found in human tumor samples and absent in normal prostate tissue. No consistent response to EMP was observed in enhanced green fluorescent protein (EGFP)-tagged lipophilin C-transfected PC3 cells compared with parental controls. Among these EGFP-lipophilin C clones, no direct correlation between response to EMP treatment (IC50 values) and EGFP expression was observed (p = 0.73). Lipophilin C mRNA levels did not vary significantly between wild-type and estramustine-resistant cells in prostate (DU145 and PC3) and ovarian (SKOV3) cancer cell lines. Overall, these results suggest that lipophilins are not specific determinants of estramustine efficacy. PMID: 16120813 [PubMed - indexed for MEDLINE]

January 23, 2006

Long-term outcomes of 60 Gy conventional radiotherapy combined with androgen deprivation for localized or locally advanced prostate cancer.


Long-term outcomes of 60 Gy conventional radiotherapy combined with androgen deprivation for localized or locally advanced prostate cancer.
Related Articles Long-term outcomes of 60 Gy conventional radiotherapy combined with androgen deprivation for localized or locally advanced prostate cancer. Jpn J Clin Oncol. 2005 Nov;35(11):655-9 Authors: Hashine K, Numata K, Azuma K, Sumiyoshi Y, Kataoka M BACKGROUND: Until 1998 in Japan, very few institutions were treating prostate cancer solely with radiotherapy (RT) >70 Gy and most were using < or =65 Gy in combination with hormone therapy. The present study reports the long-term results of RT combined with hormone therapy for localized and locally advanced prostate cancer. METHODS: We investigated 57 patients who were treated by external beam RT plus hormone therapy (median age 79 years, median prostate-specific antigen concentration 15.0 ng/ml) between 1992 and 1998. Patients received 40 Gy of radiation to the pelvis and an additional 20 Gy as a prostatic boost. Hormone therapy was begun on the first day of irradiation and continued thereafter. RESULTS: The median follow-up was 93.3 months and the 5 and 10 year actual overall survival rates were 67.8 and 32.6%, respectively, with 5 and 10 year cause-specific survival rates of 97.9 and 95.0%, respectively. The expected survival rate was 66.2% at 5 years, and overall survival was above expected survival. Only one patient developed severe proctitis (Grade 3). The 5 year occurrence of Grade 1/2 genitourinary toxicity was 23.2%. CONCLUSIONS: Combined RT and hormone therapy has a good long-term outcome without severe adverse events. The overall survival rate compares well with the expected survival rate. PMID: 16275680 [PubMed - indexed for MEDLINE]

January 21, 2006

Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data.


Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data.
Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med. 2005 Sep;2(5):658-67 Authors: Montorsi F, McCullough A Introduction. Radical prostatectomy is a frequently used treatment option for prostate cancer; however, prostatectomy is often associated with significant morbidity, including erectile dysfunction (ED). Aim. To analyze the efficacy of sildenafil citrate in treating ED after radical prostatectomy. Materials and Methods. MEDLINE and CANCERLIT (1998 to January 2004) were searched for English language articles using the key words prostatectomy, sildenafil, and phosphodiesterase inhibitors. Eleven studies fulfilled the inclusion criteria: primary, discrete data sets of postprostatectomy patients with ED treated with sildenafil monotherapy. Results. Sample sizes ranged from 13 to 198 (mean age, 61 +/- 3 years). Treatment durations were 4 weeks (or more than four doses) to 1 year, and sildenafil dosing was in the recommended range (25-100 mg). Seven studies reported a response rate (range, 14%-53%) for an end point consistent with the primary analysis outcome (erection sufficient for vaginal intercourse); the combined estimate of probability of response was 35% (95% confidence interval [CI], 24%-48%). There was strong evidence for a lower response rate after non-nerve-sparing (range, 0%-15%) versus nerve-sparing surgery (range, 35%-75%; combined odds ratio [OR] = 12.1; 95% CI, 5.5-26.6) but not after unilateral (range, 10%-80%) versus bilateral nerve-sparing surgery (range, 46%-72%; combined OR = 2.21; 95% CI, 0.75-6.54). Conclusions. The results of these studies demonstrate that with sildenafil, more than one third of patients with postprostatectomy ED achieved erection sufficient for intercourse. The odds of responding improved 12-fold with preservation of at least one neurovascular bundle. Early treatment failure does not necessarily imply lack of efficacy in the future, and patients should be encouraged to continue trying sildenafil, titrating up to 100 mg as needed. Montorsi F, and McCullough A. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med 2005;2:658-667. PMID: 16422824 [PubMed - in process]

January 18, 2006

Recent neuroanatomical studies on the neurovascular bundle of the prostate and cavernosal nerves: clinical reflections on radical prostatectomy.


Recent neuroanatomical studies on the neurovascular bundle of the prostate and cavernosal nerves: clinical reflections on radical prostatectomy.
Related Articles Recent neuroanatomical studies on the neurovascular bundle of the prostate and cavernosal nerves: clinical reflections on radical prostatectomy. Asian J Androl. 2005 Dec;7(4):339-49 Authors: Yucel S, Erdogru T, Baykara M The neurovascular bundle of the prostate and cavernosal nerves have been used to describe the same structure ever since the publication of the first studies on the neuroanatomy of the lower urogenital tract of men, studies that were prompted by postoperative complications arising from radical prostatectomy. In urological surgery every effort is made to preserve or restore the neurovascular bundle of the prostate to avoid erectile dysfunction (ED). However, the postoperative potency rates are yet to be satisfactory despite all advancements in radical prostatectomy technique. As the technology associated with urological surgery develops and topographical studies on neuroanatomy are cultivated, new observations seriously challenge the classical teachings on the topography of the neurovascular bundle of the prostate and the cavernosal nerves. The present review revisits the classical and most recent data on the topographical anatomy of the neurovascular bundle of the prostate and cavernosal nerves and their implications on radical prostatectomy techniques. PMID: 16281080 [PubMed - indexed for MEDLINE]

January 13, 2006

A rare prostatic tumor in a 48-year-old man.


A rare prostatic tumor in a 48-year-old man.
Related Articles A rare prostatic tumor in a 48-year-old man. Arch Pathol Lab Med. 2005 Nov;129(11):e202-3 Authors: Angeles RM, Engel G, Weisenberg E PMID: 16253039 [PubMed - indexed for MEDLINE]

January 12, 2006

Use of a temporary plastic stent to facilitate the placement of multiple self-expanding metal stents in malignant biliary hilar strictures.


Use of a temporary plastic stent to facilitate the placement of multiple self-expanding metal stents in malignant biliary hilar strictures.
Related Articles Use of a temporary plastic stent to facilitate the placement of multiple self-expanding metal stents in malignant biliary hilar strictures. Gastrointest Endosc. 2005 Oct;62(4):605-9 Authors: Hookey LC, Le Moine O, Deviere J BACKGROUND: Although endoscopic palliation of malignant biliary hilar obstruction is preferable to surgery or percutaneous drainage, it remains technically challenging. This is especially true when multiple self-expanding metal stents (SEMS) are placed, because difficulty is commonly encountered in passing the second SEMS at the level of the previously deployed initial stent. We have devised a method of deploying multiple metal stents by using a temporary plastic stent, which makes deployment of the second stent much easier. METHODS: After guidewire placement, a plastic stent is deployed in a subhilar position. The initial SEMS is deployed, with the plastic stent maintaining a passage for the second SEMS. After the second SEMS is deployed, the plastic stent is retrieved. OBSERVATIONS: This technique has been used successfully in 7/8 patients, all of whom presented with symptomatic jaundice secondary to malignant hilar obstruction of various etiologies (cholangiocarcinoma, n=4; metastatic disease, n=3; and hepatocellular carcinoma, n=1). Drainage was successful in all cases, with significant improvement in symptoms and cholestasis. CONCLUSIONS: This simple technique lessens the technical difficulty of placing bilateral hilar SEMS. PMID: 16185978 [PubMed - indexed for MEDLINE]

January 11, 2006

IGF-II Serum Levels Increase Discrimination Between Benign Prostatic Hyperplasia and Prostate Cancer and Improve the Predictive Value of PSA in Clinical Staging.


IGF-II Serum Levels Increase Discrimination Between Benign Prostatic Hyperplasia and Prostate Cancer and Improve the Predictive Value of PSA in Clinical Staging.
Related Articles IGF-II Serum Levels Increase Discrimination Between Benign Prostatic Hyperplasia and Prostate Cancer and Improve the Predictive Value of PSA in Clinical Staging. Eur Urol. 2005 Dec 7; Authors: Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS PURPOSE: IGF-I serum levels have been demonstrated as being associated with prostate cancer (PCa) and can serve as a predictive factor for the risk of PCa development. However, the role of IGF-II in PCa and its importance as a predictive marker is still unclear. Our aim was to determine PSA and IGF-II serum levels in patients with PCa and benign prostatic hyperplasia (BPH) and to analyse the value of IGF-II as an additional predictive factor in the diagnostics of PCa. METHODS: 112 patients who underwent surgery for BPH or PCa (no hormonal treatment, no further malignancies) were included in this study ((I) 38 PCa, PSA</=15ng/ml; (II) 34 PCa, PSA>15ng/ml; (III) 40 BPH). Preoperative serum levels of total PSA and total IGF-II were determined by ELFA and ELISA, respectively. RESULTS: PSA levels were (I) 5.7+/-1.9ng/ml; (II) 25.0+/-11.5ng/ml and (III) 4.0+/-2.8ng/ml. (II) was statistically associated with a high grading (2b/3; p=0.0182), a high Gleason sum score (7-10; p=0.0049) and a non-organ confined tumor (T3/4; p=0.0009) compared to (I), all Chi(2) test. IGF-II levels were significantly higher in PCa (I+II) compared to BPH (833.8+/-238.9ng/ml vs. 633.3+/-141.4ng/ml, p<0.0001, t-test). Both PSA and IGF-II were associated with tumor staging (p=0.0097, p=0.0308; t-test). No significant correlation was observed between PSA and IGF-II levels. Logistic regression analysis revealed that the combination of PSA and IGF-II improves the prediction of tumor staging in PCa (p=0.0175 and p=0.0459, Wald test). Additionally, the combination of PSA and IGF-II can significantly increase discrimination between BPH and PCa; each p<0.0001, Wald test. CONCLUSIONS: This study provides evidence that IGF-II serum levels may serve as an additional parameter for (a) improved determination of tumor staging and (b) better discrimination between BPH and PCa. PMID: 16386354 [PubMed - as supplied by publisher]

January 07, 2006

Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer.


Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer.
Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer. Lasers Surg Med. 2006 Jan 3; Authors: Moore CM, Nathan TR, Lees WR, Mosse CA, Freeman A, Emberton M, Bown SG BACKGROUND AND OBJECTIVES: Prostate cancer is increasing in incidence, but current treatments including surgery and radiotherapy have significant side effects. This pilot study was designed to assess the potential of photodynamic therapy (PDT) using meso tetra hydroxy phenyl chlorin (mTHPC) for organ confined prostate cancer. STUDY DESIGN/PATIENTS AND METHODS: Six men with organ confined prostate cancer were photosensitised with mTHPC (0.15 mg/kg). Between 2 and 5 days later, red light (652 nm) was delivered to areas of biopsy proven cancer via fibres inserted through transperineal needles (50-100 J per site). RESULTS: After 8 of 10 PDT sessions, the prostate specific antigen (PSA) fell by up to 67%. Early MRI scans showed oedema and patchy necrosis, which resolved over 2 months. Biopsies of treated areas revealed necrosis and fibrosis at 1-2 months. CONCLUSIONS: PDT for primary prostate cancer appears safe and can reduce PSA levels. As this was a phase I study, no attempt was made to treat the whole prostate; this or targeted tumour ablation could be attempted in a phase II study with an increased number of fibres. This technique merits further investigation in early prostate cancer. Lasers Surg. Med. (c) 2005 Wiley-Liss, Inc. PMID: 16392142 [PubMed - as supplied by publisher]

An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line.


An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line.
Related Articles An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest. 2005 Nov;85(11):1392-404 Authors: Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ Metastasis is the major cause of prostate cancer deaths and there is a need for clinically relevant in vivo models allowing elucidation of molecular and cellular mechanisms underlying metastatic behavior. Here we describe the development of a new in vivo model system for metastatic prostate cancer. Pieces of prostate cancer tissue from a patient were grafted in testosterone-supplemented male NOD-SCID mice at the subrenal capsule graft site permitting high tumor take rates. After five serial transplantations, the tumor tissues were grafted into mouse prostates. Resulting tumors and suspected metastatic lesions were subjected to histopathological and immunohistochemical analysis. Samples of metastatic tissue were regrafted in mouse anterior prostates and their growth and spread examined, leading to isolation from lymph nodes of a metastatic subline, PCa1-met. Orthotopic grafting of PCa1-met tissue in 47 hosts led in all cases to metastases to multiple organs (lymph nodes, lung, liver, kidney, spleen and, notably, bone). Histopathological analysis showed strong similarity between orthotopic grafts and their metastases. The latter were of human origin as indicated by immunostaining using antibodies against human mitochondria, androgen receptor, prostate-specific antigen and Ki-67. Spectral karyotyping showed few chromosomal alterations in the PCa1-met subline. This study indicates that transplantable subrenal capsule xenografts of human prostate cancer tissue in NOD-SCID mice can, as distinct from primary cancer tissue, be successfully grown in the orthotopic site. Orthotopic xenografts of the transplantable tumor lines and metastatic sublines can be used for studying various aspects of metastatic prostate cancer, including metastasis to bone. PMID: 16155594 [PubMed - indexed for MEDLINE]

January 02, 2006

[Subcapsular orchiectomy in the treatment of prostate cancer: results]


[Subcapsular orchiectomy in the treatment of prostate cancer: results]
Related Articles [Subcapsular orchiectomy in the treatment of prostate cancer: results] Arch Esp Urol. 2005 May;58(4):305-8 Authors: Pascual Mateo C, Luján Galán M, Santos Arrontes D, Berenguer Sánchez A OBJECTIVES: To analyze the role of orchiectomy in the management of metastasic prostate cancer in our environment. METHODS: We studied 76 patients with the diagnosis of prostate cancer who underwent subcapsular orchiectomy. RESULTS: Mean age was 72 years, median Gleason score was 7, and only 17% had organ confined tumors. Mean follow-up was 2.3 yr. and hospital stay median three days. Ten of the 76 patients in the study died from cancer, being overall five-year survival 75%. Regarding cost analysis, surgical castration was cheaper in the long-term but has the disadvantage of its greater psychological impact. CONCLUSIONS: Orchiectomy is a valid hormonal blockade option when estimated patient survival is longer than one year. PMID: 15989093 [PubMed - indexed for MEDLINE]

December 29, 2005

Emerging minimally invasive techniques for treating localized prostate cancer.


Emerging minimally invasive techniques for treating localized prostate cancer.
Related Articles Emerging minimally invasive techniques for treating localized prostate cancer. BJU Int. 2005 Dec;96(9):1230-4 Authors: Ahmed S, Lindsey B, Davies J PMID: 16287436 [PubMed - indexed for MEDLINE]

December 22, 2005

Computing intraoperative dosimetry for prostate brachytherapy using TRUS and fluoroscopy.


Computing intraoperative dosimetry for prostate brachytherapy using TRUS and fluoroscopy.
Related Articles

Computing intraoperative dosimetry for prostate brachytherapy using TRUS and fluoroscopy.

Acad Radiol. 2005 Oct;12(10):1262-72

Authors: French D, Morris J, Keyes M, Goksel O, Salcudean S

RATIONALE AND OBJECTIVES: There is a need to provide real-time dosimetric feedback during prostate brachytherapy based on the location of the implanted seeds. The objective of our approach is to develop a system to accurately locate seeds with minimal impact on the current protocol for prostate brachytherapy and without additional imaging equipment. MATERIALS AND METHODS: A new approach for intraoperatively computing dosimetry for prostate brachytherapy is presented. The approach uses transrectal ultrasound (TRUS) and fluoroscopic images. A fluoroscopic image of the TRUS probe is required to register the fluoroscopic and ultrasound images. The C-arm is not moved during the procedure and all images are acquired from the same C-arm angles. A needle path is interpolated for each needle based on the location of the needle tip in TRUS images and the known entry point of the needle. Throughout the procedure, fluoroscopic images are acquired to determine the coronal plane coordinates of the seeds and the remaining coordinate of each seed is computed from the needle path. For accurate results, intraoperative seed motion tracking is advised and a method to achieve such tracking is also presented. RESULTS: Experimentally, the TRUS and fluoroscopic images are registered with a mean and maximum error of 1.3 mm and 5.8 mm, respectively. In a phantom, 12 seeds are located using our approach and compared with the known locations, with a mean error in the x, y, and z direction of 0.96 mm, 0.33, and 0.68 mm, respectively, and a corresponding maximum error of 1.85 mm, 0.56 mm, and 1.63 mm. Experimental results show motion tracking in the y-direction with submillimeter accuracy. The feasibility of our approach is tested on five cases of clinical data using a semiautomated version of our system and the resulting dosimetry is compared with that found using postoperative computed tomography images. The D90 and V100 metrics computed using our approach and the computed tomography images differ by a maximum of 16.6% and 1.7%, respectively. CONCLUSIONS: TRUS can be combined with single pose fluoroscopic images to compute delivered dose intraoperatively for prostate brachytherapy. Phantom results demonstrate the accuracy of the method and preliminary clinical results show its potential.

PMID: 16179203 [PubMed - indexed for MEDLINE]


French D, Morris J, Keyes M, Goksel O, Salcudean S

December 19, 2005

FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent


FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer.
Related Articles

FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer.

Int J Cancer. 2005 Dec 20;117(6):1039-48

Authors: Chua CW, Lee DT, Ling MT, Zhou C, Man K, Ho J, Chan FL, Wang X, Wong YC

FTY720, a derivative of fungus, has demonstrated dramatic anticancer effect in several malignancies recently. Our study evaluates the therapeutic potential of FTY720 in the treatment of androgen-independent prostate cancer using a human prostate cancer xenograft in nude mice. CWR22R, an androgen-independent human prostate tumor xenograft was inoculated into castrated nude mice and the animals were administrated with either normal saline or FTY720 (10 mg/kg) through intraperitoneal (i.p.) injection for 20 days. Body weight and tumor volume were recorded every 2 days, and serum prostate specific antigen (PSA) levels were also measured before and after the treatment. The effect of FTY720 on tumor cell proliferation was examined using antibodies against PCNA and Ki-67 by immunohistochemical staining, MTT assay and colony forming assay, whereas apoptotic effect of FTY720 was evaluated by TUNEL assay and immunostaining using antibodies against cleaved caspase 3 and Bcl-2. In addition, the potential inhibitory effect of FTY720 on prostate cancer angiogenesis and metastasis was investigated by immunostaining of CD31, VEGF, E-cadherin and beta-catenin. Our results showed that FTY720 treatment led to suppression of CWR22R tumor growth without causing any detectable side effects in nude mice. The FTY720-induced tumor suppression was correlated with decreased serum PSA level as well as reduced proliferation rate, suppression of angiogenic factors, and restoration of E-cadherin and beta-catenin expression. In addition, the FTY720-treated tumors showed increased apoptosis rate demonstrated by increased TUNEL- and cleaved caspase 3-positive cells, and decreased Bcl-2 expression. Our results suggest a potential novel agent in the suppression of androgen-independent prostate cancer.

PMID: 15986440 [PubMed - indexed for MEDLINE]


Chua CW, Lee DT, Ling MT, Zhou C, Man K, Ho J, Chan FL, Wang X, Wong YC

Stromal expression of connective tissue growth factor promotes angiogenesis and


Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis.
Related Articles

Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis.

Cancer Res. 2005 Oct 1;65(19):8887-95

Authors: Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR

Our previous studies have defined reactive stroma in human prostate cancer and have developed the differential reactive stroma (DRS) xenograft model to evaluate mechanisms of how reactive stroma promotes carcinoma tumorigenesis. Analysis of several normal human prostate stromal cell lines in the DRS model showed that some rapidly promoted LNCaP prostate carcinoma cell tumorigenesis and others had no effect. These differential effects were due, in part, to elevated angiogenesis and were transforming growth factor (TGF)-beta1 mediated. The present study was conducted to identify and evaluate candidate genes expressed in prostate stromal cells responsible for this differential tumor-promoting activity. Differential cDNA microarray analyses showed that connective tissue growth factor (CTGF) was expressed at low levels in nontumor-promoting prostate stromal cells and was constitutively expressed in tumor-promoting prostate stromal cells. TGF-beta1 stimulated CTGF message expression in nontumor-promoting prostate stromal cells. To evaluate the role of stromal-expressed CTGF in tumor progression, either engineered mouse prostate stromal fibroblasts expressing retroviral-introduced CTGF or 3T3 fibroblasts engineered with mifepristone-regulated CTGF were combined with LNCaP human prostate cancer cells in the DRS xenograft tumor model under different extracellular matrix conditions. Expression of CTGF in tumor-reactive stroma induced significant increases in microvessel density and xenograft tumor growth under several conditions tested. These data suggest that CTGF is a downstream mediator of TGF-beta1 action in cancer-associated reactive stroma and is likely to be one of the key regulators of angiogenesis in the tumor-reactive stromal microenvironment.

PMID: 16204060 [PubMed - indexed for MEDLINE]


Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR

December 14, 2005

prostate cancer surgery; +102 new citations 102 new PubMed citations


prostate cancer surgery; +102 new citations

102 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results:

prostate cancer surgery

These PubMed results were generated on 2005/12/14

PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources.


PubMed

December 12, 2005

[Update of the treatment of advanced prostate cancer and management


[Update of the treatment of advanced prostate cancer and management of its complications.]
Related Articles

[Update of the treatment of advanced prostate cancer and management of its complications.]

Med Clin (Barc). 2005 Nov 12;125(17):671-8

Authors: Gil-Bazo I, Ignacio Martínez-Salamanca J, Bianco Jr FJ

Prostate adenocarcinoma is the leading cause of cancer in Spain, among men older than 65. 1,200 new cases out of every 100,000 males are diagnosed with prostate cancer on an annual basis. In the United States, this illness represents the second leading cause of death due to cancer in males. In those patients whose prostate tumors progress after surgery or radiotherapy, or have metastatic disease when diagnosed, a systemic approach in order to improve their quality of life and overall survival is mandatory. First line hormone therapies usually reach a proper control of the tumor maintaining an acceptable quality of life. However, most of these tumors becomes androgen-independent over time and behave as a more aggressive cancer type. In these patients, combination therapy protocols have recently demonstrated a benefit not only in terms of symptoms control and response rates but also in improving survival. In addition, several new molecules are currently under study. The accurate knowledge of the symptoms due to disease spreading as well as treatment's side effects is necessary to provide an appropriate palliative management that contributes to an improvement of the quality of life in advanced prostate cancer patients.

PMID: 16324498 [PubMed - in process]


Gil-Bazo I, Ignacio Mart nez-Salamanca J, Bianco Jr FJ

December 08, 2005

[Update of the treatment of advanced prostate cancer and management


[Update of the treatment of advanced prostate cancer and management of its complications.]
Related Articles

[Update of the treatment of advanced prostate cancer and management of its complications.]

Med Clin (Barc). 2005 Nov 12;125(17):671-8

Authors: Gil-Bazo I, Ignacio Mart nez-Salamanca J, Bianco Jr FJ

Prostate adenocarcinoma is the leading cause of cancer in Spain, among men older than 65. 1,200 new cases out of every 100,000 males are diagnosed with prostate cancer on an annual basis. In the United States, this illness represents the second leading cause of death due to cancer in males. In those patients whose prostate tumors progress after surgery or radiotherapy, or have metastatic disease when diagnosed, a systemic approach in order to improve their quality of life and overall survival is mandatory. First line hormone therapies usually reach a proper control of the tumor maintaining an acceptable quality of life. However, most of these tumors becomes androgen-independent over time and behave as a more aggressive cancer type. In these patients, combination therapy protocols have recently demonstrated a benefit not only in terms of symptoms control and response rates but also in improving survival. In addition, several new molecules are currently under study. The accurate knowledge of the symptoms due to disease spreading as well as treatment's side effects is necessary to provide an appropriate palliative management that contributes to an improvement of the quality of life in advanced prostate cancer patients.

PMID: 16324498 [PubMed - in process]


Gil-Bazo I, Ignacio Mart nez-Salamanca J, Bianco Jr FJ

December 04, 2005

Elevated expression of angiogenin in prostate cancer and its precursors.


Elevated expression of angiogenin in prostate cancer and its precursors.

Elevated expression of angiogenin in prostate cancer and its precursors.

Clin Cancer Res. 2005 Dec 1;11(23):8358-63

Authors: Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA, Cheng L

PURPOSE: Angiogenin is a polypeptide involved in the formation and establishment of new blood vessels necessary for growth and metastasis of numerous malignant neoplasms, including prostatic adenocarcinoma. Antiangiogenin therapy inhibits the establishment, growth, and metastasis of prostatic adenocarcinoma in animal studies. In this study, we have investigated the expression of angiogenin in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and adjacent benign prostatic epithelium in a large cohort of prostatectomy specimens.Methods: We have studied the expression of angiogenin by immunohistochemistry in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and adjacent benign prostatic tissue in 107 human total prostatectomy specimens.RESULTS: The percentage of cells staining positively for angiogenin in benign prostatic glandular epithelium (mean = 17%) was significantly less than for high-grade prostatic intraepithelial neoplasia (mean = 58%, P < 0.001) and prostatic adenocarcinoma (mean = 60%, P < 0.001). Compared with adjacent benign prostatic epithelium, the staining intensity was significantly greater in high-grade prostatic intraepithelial neoplasia (P < 0.001) and prostatic adenocarcinoma (P < 0.001). Furthermore, staining intensity has significantly stronger in prostatic adenocarcinoma versus high-grade prostatic intraepithelial neoplasia (P = 0.0023). However, there was no correlation of angiogenin expression with various clinical and pathologic variables examined, including age at surgery, Gleason scores, pathologic stage, tumor extent, angiolymphatic invasion, extraprostatic extension, seminal vesical invasion, lymph node metastasis, surgical margin status, presence of prostatic intraepithelial neoplasia, and perineural invasion.CONCLUSION: Angiogenin expression in prostatic tissue increases as prostatic epithelial cells evolve from a benign to an invasive phenotype. The increasing expression of prostatic adenocarcinoma in the progression from benign prostate to high-grade prostatic intraepithelial neoplasia and ultimately to prostatic adenocarcinoma are consistent with previous studies showing the influential role that angiogenin plays in the growth, invasion, and metastasis of prostatic adenocarcinoma and many other malignant tumors.

PMID: 16322296 [PubMed - in process]


Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA, Cheng L

December 03, 2005

Elevated expression of angiogenin in prostate cancer and its precursors.


Elevated expression of angiogenin in prostate cancer and its precursors.

Elevated expression of angiogenin in prostate cancer and its precursors.

Clin Cancer Res. 2005 Dec 1;11(23):8358-63

Authors: Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA, Cheng L

PURPOSE: Angiogenin is a polypeptide involved in the formation and establishment of new blood vessels necessary for growth and metastasis of numerous malignant neoplasms, including prostatic adenocarcinoma. Antiangiogenin therapy inhibits the establishment, growth, and metastasis of prostatic adenocarcinoma in animal studies. In this study, we have investigated the expression of angiogenin in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and adjacent benign prostatic epithelium in a large cohort of prostatectomy specimens.Methods: We have studied the expression of angiogenin by immunohistochemistry in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and adjacent benign prostatic tissue in 107 human total prostatectomy specimens.RESULTS: The percentage of cells staining positively for angiogenin in benign prostatic glandular epithelium (mean = 17%) was significantly less than for high-grade prostatic intraepithelial neoplasia (mean = 58%, P < 0.001) and prostatic adenocarcinoma (mean = 60%, P < 0.001). Compared with adjacent benign prostatic epithelium, the staining intensity was significantly greater in high-grade prostatic intraepithelial neoplasia (P < 0.001) and prostatic adenocarcinoma (P < 0.001). Furthermore, staining intensity has significantly stronger in prostatic adenocarcinoma versus high-grade prostatic intraepithelial neoplasia (P = 0.0023). However, there was no correlation of angiogenin expression with various clinical and pathologic variables examined, including age at surgery, Gleason scores, pathologic stage, tumor extent, angiolymphatic invasion, extraprostatic extension, seminal vesical invasion, lymph node metastasis, surgical margin status, presence of prostatic intraepithelial neoplasia, and perineural invasion.CONCLUSION: Angiogenin expression in prostatic tissue increases as prostatic epithelial cells evolve from a benign to an invasive phenotype. The increasing expression of prostatic adenocarcinoma in the progression from benign prostate to high-grade prostatic intraepithelial neoplasia and ultimately to prostatic adenocarcinoma are consistent with previous studies showing the influential role that angiogenin plays in the growth, invasion, and metastasis of prostatic adenocarcinoma and many other malignant tumors.

PMID: 16322296 [PubMed - in process]


Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA, Cheng L

November 29, 2005

Epidural spinal cord compression. Related Articles Epidural spinal cord compression.


Epidural spinal cord compression.
Related Articles

Epidural spinal cord compression.

Crit Rev Oncol Hematol. 2005 Nov 22;56(3):397-406

Authors: Spinazz S, Caraceni A, Schrijvers D

Spinal cord compression from epidural metastases (epidural spinal cord compression, ESCC) is the most common neurological complication of cancer after brain metastases. Extradural compression represents 97% of spinal cord metastatic lesions. ESCC usually occurs in patients with disseminated disease. The most common tumours associated with ESCC are lung and breast cancers, followed by lymphoma, myeloma, prostate cancer and sarcoma. ESCC represents a medical emergency because delayed treatment can be responsible for irreversible deficits, such as paralysis and loss of sphincter control. Patients with ESCC require a multidisciplinary diagnostic and therapeutic approach. Clinical suspect is radiologically detected for confirmation. The median expected survival time from diagnosis usually ranges from 3 to 6 months. The nature of the primary tumour and the degree of the neurological deficit are the most important factors affecting survival. The lack of prospective randomized trials makes the optimal treatment of ESCC controversial and the decision is to be tailored to the individual. Treatment options include: bed rest, administration of corticosteroids, surgery followed by radiation therapy, radiotherapy alone and, to a limited extent, chemotherapy and hormonal therapy.

PMID: 16310372 [PubMed - as supplied by publisher]


Spinazz S, Caraceni A, Schrijvers D

Epidural spinal cord compression. Related Articles Epidural spinal cord compression.


Epidural spinal cord compression.
Related Articles

Epidural spinal cord compression.

Crit Rev Oncol Hematol. 2005 Nov 22;56(3):397-406

Authors: Spinazz S, Caraceni A, Schrijvers D

Spinal cord compression from epidural metastases (epidural spinal cord compression, ESCC) is the most common neurological complication of cancer after brain metastases. Extradural compression represents 97% of spinal cord metastatic lesions. ESCC usually occurs in patients with disseminated disease. The most common tumours associated with ESCC are lung and breast cancers, followed by lymphoma, myeloma, prostate cancer and sarcoma. ESCC represents a medical emergency because delayed treatment can be responsible for irreversible deficits, such as paralysis and loss of sphincter control. Patients with ESCC require a multidisciplinary diagnostic and therapeutic approach. Clinical suspect is radiologically detected for confirmation. The median expected survival time from diagnosis usually ranges from 3 to 6 months. The nature of the primary tumour and the degree of the neurological deficit are the most important factors affecting survival. The lack of prospective randomized trials makes the optimal treatment of ESCC controversial and the decision is to be tailored to the individual. Treatment options include: bed rest, administration of corticosteroids, surgery followed by radiation therapy, radiotherapy alone and, to a limited extent, chemotherapy and hormonal therapy.

PMID: 16310372 [PubMed - as supplied by publisher]


Spinazz S, Caraceni A, Schrijvers D

November 28, 2005

CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate


CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro.
Related Articles

CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro.

Aging Cell. 2005 Dec;4(6):291-8

Authors: Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA

Summary The direct relationship between the aging process and the incidence and prevalence of both benign prostatic hyperplasia (BPH) and prostate cancer (PCa) implies that certain risk factors associated with the development of both diseases increase with the aging process. In particular, both diseases share an overly proliferative phenotype, suggesting that mechanisms that normally act to suppress cellular proliferation are disrupted or rendered dysfunctional as a consequence of the aging process. We propose that one such mechanism involves changes in the prostate microenvironment, which 'evolves' during the aging process and disrupts paracrine interactions between epithelial and associated stromal fibroblasts. We show that stromal fibroblasts isolated from the prostates of men 63-81 years of age at the time of surgery express and secrete higher levels of the CXCL12 chemokine compared with those isolated from younger men, and stimulate CXCR4-mediated signaling pathways that induce cellular proliferation. These studies represent an important first step towards a mechanistic elucidation of the role of aging in the etiology of benign and malignant prostatic diseases.

PMID: 16300481 [PubMed - in process]


Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA

November 24, 2005

CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate


CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro.
Related Articles

CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro.

Aging Cell. 2005 Dec;4(6):291-8

Authors: Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA

Summary The direct relationship between the aging process and the incidence and prevalence of both benign prostatic hyperplasia (BPH) and prostate cancer (PCa) implies that certain risk factors associated with the development of both diseases increase with the aging process. In particular, both diseases share an overly proliferative phenotype, suggesting that mechanisms that normally act to suppress cellular proliferation are disrupted or rendered dysfunctional as a consequence of the aging process. We propose that one such mechanism involves changes in the prostate microenvironment, which 'evolves' during the aging process and disrupts paracrine interactions between epithelial and associated stromal fibroblasts. We show that stromal fibroblasts isolated from the prostates of men 63-81 years of age at the time of surgery express and secrete higher levels of the CXCL12 chemokine compared with those isolated from younger men, and stimulate CXCR4-mediated signaling pathways that induce cellular proliferation. These studies represent an important first step towards a mechanistic elucidation of the role of aging in the etiology of benign and malignant prostatic diseases.

PMID: 16300481 [PubMed - in process]


Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA

November 13, 2005

[Budd-Chiari syndrome in a patient with paroxysmal nocturnal haemoglobinuria] Related


[Budd-Chiari syndrome in a patient with paroxysmal nocturnal haemoglobinuria]
Related Articles

[Budd-Chiari syndrome in a patient with paroxysmal nocturnal haemoglobinuria]

Dtsch Med Wochenschr. 2005 Oct 7;130(40):2257-60

Authors: Balta Z, Nattermann J, Flacke S, Sauerbruch T

HISTORY AND CLINICAL FINDINGS: A 61-year-old man with dyspnea and diffuse abdominal pain due to increasing ascites caused by liver cirrhosis of unknown etiology was admitted for consideration of transjugular intrahepatic portosystemic stent-shunting (TIPSS). The patient's medical history included paroxysmal nocturnal hemoglobinuria (PNH), presenting as slight hemolysis diagnosed 24 years previously. One year before the patient underwent radical retropubic prostatectomy for a localized prostate cancer. Shortly after this intervention he developed ascites. INVESTIGATIONS: Color Doppler ultrasonography revealed an abnormal flow in the major hepatic veins. Transjugular liver biopsy indicated hepatic a circulatory disorder. Hepatic venography revealed the so-called "spider web" pattern characteristic for the Budd-Chiari syndrome. The hypercoagulable state due to paroxysmal nocturnal hemoglobinuria was accentuated by manipulation on the prostate during prostatectomy and presumably resulted in a thrombotic obstruction of the hepatic veins. TREATMENT AND CLINICAL COURSE: After exclusion of contraindications a transjugular intrahepatic portosystemic stent shunt (TIPSS) was performed, which led to a decrease of portal pressure. Signs of portal hypertension such as esophageal varices and ascites resolved completely. The patient has been free of complaints for one year. CONCLUSION: We assume that a hypercoagulopathy due to asymptomatic paroxysmal nocturnal hemoglobinuria resulted in Budd-Chiari syndrome when boosted by postoperative release of procoagulation factors in the thrombokinase-rich prostate. TIPSS is a therapeutic option in these patients.

PMID: 16208599 [PubMed - indexed for MEDLINE]


Balta Z, Nattermann J, Flacke S, Sauerbruch T